Back to search

Peptide record

TPDB91328

Cecropin B Antibacterial Anticancer Antifungal Antiparasitic Toxicity standard

35 amino acids

3D PDB MODEL

Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.

TPDB ID TPDB91328

Peptide_Name

Cecropin B

Activity

Antibacterial Anticancer Antifungal Antiparasitic Toxicity

Activity_category_statistics

Anti-infective peptides Cancer-related peptides Toxicity and safety peptides

Database_Source

AntiBP3 dbAMP DRAMP Peptipedia AntiCP 2.0 CancerPPD 2.0 SATPdb dbACP iACP-DRLF AFP-GFuse Antifungipept CAFPdb ToxinPred 3.0

Sequence_Type

standard

Has_Modification No

Description A 35-aa standard natural multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, dbAMP, DRAMP, and other sources, with an available 3D structural model.

Modification

C-terminal: Amidation

Sequence

KWKIFKKIEKVGRNIRNGIIKAGPAVAVLGEAKAL-NH2

FASTA

>TPDB91328|Antibacterial;Anticancer;Antifungal;Antiparasitic;Toxicity|length=35
KWKIFKKIEKVGRNIRNGIIKAGPAVAVLGEAKAL-NH2

Formula C177H303N51O42

Absent Amino Acids DCQHMSTY

Common Amino Acids K

Mass 3817.67

PI 11.23

Basic Residues 9

Acidic Residues 2

Hydrophobic Residues 17

Net Charge +7

Boman Index 7.63

Hydrophobicity 0.003

Aliphatic Index 117.14

Half Life

Mammalian: 1.3 hour Yeast: 3 min E.coli: 2 min

Extinction Coefficient Cystines 5500

Absorbance 280nm 144.07

Polar Residues 2

number

Amino Acid Distribution

A: 5 R: 2 N: 2 D: 0 C: 0 E: 2 Q: 0 G: 4 H: 0 I: 5 L: 2 K: 7 M: 0 F: 1 P: 1 S: 0 T: 0 W: 1 Y: 0 V: 3

Length

Formula

C177H303N51O42

Mass

3817.67

11.23

Net Charge

Boman Index

7.63

Hydrophobicity

0.003

C_terminal_Modification

Amidation

Chirality

Linear_or_Cyclic

Linear

N_terminal_Modification

Free

Nature

Antimicrobial

Origin

Chinese oak silk moth

Evidence 1 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50=161.76 µg/ml

Detail Source Activity Anticancer

Activity Measurement 161.76 µg/mL

Target

Cancer Type Bladder Cancer

Cell Line 486P

Tissue Affected Bladder

Assay & Model

Assay WST-1 assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2008

Other

Source Activity Label	Source Definition
Anticancer	CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.

Evidence 2 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50=184.81 µg/ml

Detail Source Activity Anticancer

Activity Measurement 184.81 µg/mL

Target

Cancer Type Bladder Cancer

Cell Line RT4

Tissue Affected Bladder

Assay & Model

Assay WST-1 assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2008

Evidence 3 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50=115.12 µg/ml

Detail Source Activity Anticancer

Activity Measurement 115.12 µg/mL

Target

Cancer Type Bladder Cancer

Cell Line 647V

Tissue Affected Bladder

Assay & Model

Assay WST-1 assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2008

Evidence 4 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50=97.93 µg/ml

Detail Source Activity Anticancer

Activity Measurement 97.93 µg/mL

Target

Cancer Type Bladder Cancer

Cell Line J82

Tissue Affected Bladder

Assay & Model

Assay WST-1 assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2008

Evidence 5 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50=87.47 µg/ml

Detail Source Activity Anticancer

Activity Measurement 87.47 µg/mL

Target

Cancer Type Bladder Cancer

Cell Line 486P

Tissue Affected Bladder

Assay & Model

Assay Cell Viability assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2008

Evidence 6 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50=92.9 µg/ml

Detail Source Activity Anticancer

Activity Measurement 92.9 µg/mL

Target

Cancer Type Bladder Cancer

Cell Line RT4

Tissue Affected Bladder

Assay & Model

Assay Cell Viability assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2008

Evidence 7 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50=61.86 µg/ml

Detail Source Activity Anticancer

Activity Measurement 61.86 µg/mL

Target

Cancer Type Bladder Cancer

Cell Line 647V

Tissue Affected Bladder

Assay & Model

Assay Cell Viability assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2008

Evidence 8 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50=77.51 µg/ml

Detail Source Activity Anticancer

Activity Measurement 77.51 µg/mL

Target

Cancer Type Bladder Cancer

Cell Line J82

Tissue Affected Bladder

Assay & Model

Assay Cell Viability assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2008

Evidence 9 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50=232.4 µg/ml

Detail Source Activity Anticancer

Activity Measurement 232.4 µg/mL

Target

Cancer Type Bladder Cancer

Cell Line 486P

Tissue Affected Bladder

Assay & Model

Assay LDH leakage assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2008

Evidence 10 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50=240.4 µg/ml

Detail Source Activity Anticancer

Activity Measurement 240.4 µg/mL

Target

Cancer Type Bladder Cancer

Cell Line RT4

Tissue Affected Bladder

Assay & Model

Assay LDH leakage assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2008

Evidence 11 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50=181.1 µg/ml

Detail Source Activity Anticancer

Activity Measurement 181.1 µg/mL

Target

Cancer Type Bladder Cancer

Cell Line 647V

Tissue Affected Bladder

Assay & Model

Assay LDH leakage assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2008

Evidence 12 Activity

Activity

Activity Endpoint Cytotoxicity

Activity Raw

Cytotoxicity=196.3 µg/ml

Detail Source Activity Anticancer

Target

Cancer Type Bladder Cancer

Cell Line J82

Tissue Affected Bladder

Assay & Model

Assay LDH leakage assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2008